Scientists have developed new compounds that block the interaction between the RAS gene and the PI3K enzyme, a key driver of cancer growth, while sparing normal cellular functions. RAS mutations keep the gene permanently active, causing uncontrolled cell proliferation, but directly targeting RAS or PI3K has been challenging due to their roles in essential processes like insulin signaling, where full inhibition can lead to high blood sugar.
The novel small molecules covalently bind to a specific site on PI3K, preventing RAS from activating the enzyme without disrupting its normal metabolic functions. In mouse models of RAS-mutated lung cancer, these compounds halted tumor growth without raising glucose levels. When combined with other targeted therapies, they achieved stronger, longer-lasting tumor suppression and also showed activity against HER2-mutated tumors, indicating broader potential.
Encouraged by these results, the therapy has entered its first human clinical trial to assess safety, tolerability, and preliminary efficacy in patients with RAS- or HER2-driven cancers. This approach offers a promising path to safe, effective RAS-pathway inhibition.